Tackling Drug Shortages: An In-Depth Systematic Review Protocol
Main Article Content
Keywords
Drug, medicine shortages, Protocol, Systematic , Review
Abstract
Addressing global drug shortages demands proactive measures. Enhanced reporting, supply chain policies, and quality systems are crucial to minimize it. Notably, there’s a lack of systematic review on the reasons of drug shortage. To fill this gap, our study will adhere to PRISMA guidelines for systematic reviews, conducting a thorough literature search across various databases using specific descriptors related to drug shortages. Articles will be screened for relevance, with eligibility assessed by two independent reviewers and disagreements resolved through consensus. Duplicates will be removed, and data will be extracted using a standardized form. Quality assessment will employ the Mixed Methods Appraisal Tool, with appraisals conducted independently by two reviewers and discrepancies resolved through consensus. A narrative synthesis approach will be used to synthesize findings, initially presenting results in tabular form before discussing and structuring them into themes. Drug shortages are caused by a range of factors, including issues with drug supply, demand, and regulatory challenges. These factors interact in complex ways, requiring comprehensive solutions to effectively address the scarcity of medicines.
References
1. Phuong JM, Penm J, Chaar B, Oldfield LD, Moles R. The impacts of medication shortages on patient outcomes: A scoping
review. PLoS One . 2019;14(5): 1-12. https://doi.org/10.1371/journal.pone.0215837
2. Atif M, Sehar A, Malik I, Mushtaq I, Ahmad N, Babar ZU. What impact does medicines shortages have on patients? A qualitative
study exploring patients’ experience and views of healthcare professionals. BMC Health Serv Res. 2021;21(1): 1-10. https://
doi: 10.1186/s12913-021-06812-7.
3. Hedman L. Global approaches to addressing shortages of essential medicines in health systems. WHO Drug Information. 2016;
30(2):180–185. https://iris.who.int/handle/10665/331028
4. Omer S, Pan M , Ali S, Shukar S , Fang Y, Yang C. Perceptions of pharmacists towards drug shortages in the healthcare system
of Pakistan and its impact on patient care: findings from a cross-sectional survey. BMJ Open. 2021;11(12): 1-11. https://doi:
10.1136/bmjopen-2021-050196.
5. Tan YX, Moles RJ, Chaar BB. Medicine shortages in Australia: causes, impact and management strategies in the community
setting. Int J Clin Pharm. 2016; 38(5):1133–41. https://doi: 10.1007/s11096-016-0342-1
6. Thoma BN, Li J, McDaniel CM, Wordell CJ, Cavarocchi N, Pizzi LT. Clinical and economic impact of substituting dexmedetomidine
for propofol due to a US drug shortage: Examination of coronary artery bypass graft patients at an urban medical centre.
PharmacoEconomics. 2014; 32(2):149–57. https://doi:10.1007/s11096-020-01103-3
7. Al Ruthia YS, Al Kofide H, Al Ajmi R, Balkhi B, Alghamdi A, Al Nasser A. Drug shortages in large hospitals in Riyadh: A cross- sectional study. Ann Saudi Med. 2017; 37(5):375–85. https://doi:doi: 10.5144/0256-4947.2017.375.
8. Dill S, Ahn J. Drug Shortages in developed countries-reasons, therapeutic consequences, and handling. Eur J Clin Pharmacol.
2014;70: 1405–1412 https://doi: 10.1007/s00228-014-1747-1
9. McLaughlin M, Kotis D, Thomson K, Harrison M, Fennessy G, Postelnick M. Effects on patient care caused by drug shortages: A
survey. J Manag Care Pharm. 2013; 19(9):783–8 https://doi: 10.18553/jmcp.2013.19.9.783
10. Souliotis K, Papageorgiou M, Politi A, Ioakeimidis D, Sidiropoulos P. Barriers to accessing biologic treatment for rheumatoid
arthritis in Greece: The unseen impact of the fiscal crisis—The Health Outcomes Patient Environment (HOPE) study. Rheumatol
Int. 2014; 34(1):25–33 https:// doi: 10.1007/s00296-013-2866-1
11. Atif M, Malik I, Mushtaq I, Asghar S. Medicines shortages in Pakistan: a qualitative study to explore current situation, reasons
and possible solutions to overcome the barriers. BMJ Open. 2019;9(9): 1-10 https:// doi: 10.1136/bmjopen-2018-027028.
12. Ventola CL. The Drug shortage crisis in the United States: causes, impact, and management strategies. Pharm Ther. 2011;36:
740-8 https://pubmed.ncbi.nlm.nih.gov/22346307
13. Shukar S, Zahoor F, Hayat K, Saeed A, Gillani AH, Omer S, Hu S, Babar ZU, Fang Y, Yang C. Drug shortage: causes, impact, and
mitigation strategies. Front Pharmacol. 2021;9: 1-12 https://doi.org/10.3389/fphar.2021.693426
14. Videau M, Chemali L, Stucki C, Saavedra-Mitjans M, Largana S, Guerin, A. Drug Shortages in Canada and Selected European
Countries: a Cross-Sectional, Institution-Level Comparison. Can J Hosp Pharm.2019; 72: 1-7 https://pubmed.ncbi.nlm.nih.
gov/30828089
15. Wall S, Bangalee V. The Ketamine Crisis: Does South Africa Have a Plan B?. S Afr Med J. 2019;109: 911–913. https://doi:
10.7196/SAMJ.2019.v109i12.14188
16. Pava MLSDL, Tucker EL. Drug shortages in low- and middle-income countries: Colombia as a case study. J Pharm Policy Pract.
2022;15(1):1-4 https:// doi: 10.1186/s40545-022-00439-7
17. Khan FA. Anesthetic drugs shortage in lower and middle income countries: a safety and quality issue. Anaesth Pain Intensive
Care. 2019; 23(4): 337–339. https://www.apicareonline.com/index.php/APIC/article/view/1164/1949
18. Yang C, Wu L, Cai W, Zhu W, Shen Q, Li Z. Current situation, determinants, and solutions to drug shortages in Shaanxi province,
China: A qualitative study. PloS One. 2016; 11:1-11 https:// doi: 10.1371/journal.pone.0165183
19. Mazer-Amirshahi M, Pourmand A, Singer S, Pines JM, Anker J. Critical drug shortages: implications for emergency medicine.
Acad Emerg Med. 2014;21(6):704-11 https:// doi: 10.1111/acem.12389
20. Schwartzberg E, Ainbinder D, Vishkauzan A, Gamzu R. Drug shortages in Israel: regulatory perspectives, challenges and
solutions. Isr J Health Policy Res. 2017; 6(1): 1-7. https:// doi: 10.1186/s13584-017-0140-9
21. Awad H, Al-Zu’bi MF, Abdallah AB. A quantitative analysis of the causes of drug shortages in Jordan: a supply chain perspective.
Int J Bus Res. 2016; 9(6):1-11 https://www.ccsenet.org/journal/index.php/ibr/article/view/57405
22. Walker J, Chaar BB, Vera N, Pillai AS, Lim JS, Bero L, Moles RJ. Medicine shortages in Fiji: A qualitative exploration of stakeholders’
views. PLoS One.2017 ;12(6): 1-12 https:// doi: 10.1371/journal.pone.0178429
23. Alruthia YS. Alwhaibi M, Alotaibi MF. Drug shortages in Saudi Arabia: Root causes and recommendations. Saudi Pharm J, 2018.
26(7): p. 947-951 https:// doi: 10.1016/j.jsps.2018.05.002
24. Meloni ST, Chaplin B, Idoko J. Drug resistance patterns following pharmacy stock shortage in Nigerian Antiretroviral Treatment
Program. AIDS Res Ther. 2017;14(1):1-8. https://doi: 10.1186/s12981-017-0184-5.
25. Videau M, Lebel D, Bussière JF. Drug shortages in Canada: Data for 2016-2017 and perspectives on the problem. Ann Pharm
Fr. 2019;77(3): 205-211 https:// doi: 10.1016/j.pharma.2018.11.007
26. Alsheikh M, Seoane-Vazquez E, Rittenhouse B. A comparison of drug shortages in the hospital setting in the United States and
Saudi Arabia: An exploratory analysis. Hosp Pharm. 2016; 51(5): 370-5 https:// doi: 10.1310/hpj5105-370
27. Malik M, Hassali MA, Shafie AA, Hussain A. Why hospital pharmacists have failed to manage anti-malarial drugs stock-outs in
Pakistan? A qualitative insight. Malar Res Treat. 2013; 13:1-14 https:// doi: 10.1155/2013/342843
28. Heiskanen K, Ahonen R, Kanerva R, Karttunen P, Timonen J. The reasons behind medicine shortages from the perspective of
pharmaceutical companies and pharmaceutical wholesalers in Finland. PLoS One.2017; 12(6): 1-12 https:// doi: 10.1371/
journal.pone.0179479
29. Fatima SA, Khaliq A. A survey regarding drug shortage in tertiary care hospitals of Karachi, Pakistan. J Pharm Pract Community
Med. 2017; 3:262–266. https:// doi:10.5530/jppcm.2017.4.69
30. McBride A, Holle LM, Westendorf C, Sidebottom M, Griffith N, Muller RJ, Hoffman JM. National survey on the effect of oncology
drug shortages on cancer care. Am J Health Syst Pharm. 70 (7):609–617. https:// doi: 10.2146/ajhp120563
31. Barthelemy I, Bussières JF, Bourdon O. Drug shortages and antimicrobial agents: a cross-sectional France-Canada comparison
and perspective. European Society of Clinical Pharmacy, Leuven, Belgique. Int J Clin Pharm 2012;34(5):779-94 https://indicible.
ca/urpp/20120522_RUPTURES6_Affiche.pdf
32. Wiggins BS, Nappi J, Fortier CR, Taber DJ. Cardiovascular drug shortages: Predominant etiologies, clinical implications, and
management strategies. Ann Pharmacother 2014; 48(9):1177-1186 https://doi: 10.1177/1060028014539142
33. Dave CV, Pawar A, Fox ER, Brill G, Kesselheim AS. Predictors of drug shortages and association with generic drug prices: A
retrospective cohort study. Value health. 2018 21(11):1286-1290. https:// doi: 10.1016/j.jval.2018.04.1826
34. McKenna M. Hospital pharmacists scrambling amid vast drug shortages: Emergency physicians between rock and hard place. Ann Emerg Med. 2011; 57(2):13–15. https:// doi: 10.1016/j.annemergmed.2010.12.006
35. Johnson TJ. Drug shortages: An increasing problem for patients and clinicians. S D Med. 2011; 64(1):14–15 https://pubmed.
ncbi.nlm.nih.gov/21337920
36. Kaakeh R, Sweet B, Reilly C. Impact of drug shortages on U.S. health systems. Am J Health Syst Pharm. 2011;68:1811–1819.
https:// doi: 10.2146/ajhp110210.
37. Jenks S. Efforts underway to curb drug shortages. J Natl Cancer Inst. 2011;103(12):914–915. https:// doi: 10.1093/jnci/djr234
38. Thompson C. House legislation proposes early warning system for drug shortages. Am J Health Syst Pharm. 2011;68:1379–
1381. https:// doi: 10.2146/news110052
39. Thompson C. Stakeholders in supply chain discuss shortages. Am J Health Syst Pharm. 2011; 68: 9–10 https:// doi: 10.2146/
news100088
40. Cummings MJ, Baldwin MR, Abrams D. Epidemiology, clinical course and outcomes of critically ill adults with COVID-19 in New
York City: a prospective cohort study. Lancet. 2020; 395: 1763-1770 https:// doi: 10.1016/S0140-6736(20)31189-2
41. Mori J, Hasui K, Tanimoto T, Matsumura T, Kami M. Drug Shortages After the Eastern Japan Earthquake: Experiences in a
Tertiary Referral Center. Drug Inf J. 2012;46(5):607–10 https://link.springer.com/article/10.1177/0092861512448569
42. Ayati N, Saiyarsarai P, Nikfar S. Short and Long Term Impacts of COVID-19 on the Pharmaceutical Sector. DARU J Pharm Sci
2020;28:799–805. https:// doi: 10.1007/s40199-020-00358-5
43. Rinaldi, F., de Denus, S., Nguyen, A., Nattel, S., & Bussières, J.-F. Drug shortages: patients and health care providers are all
drawing the short straw. Can J Cardiol, 2017;33(2): 283–286 https:// doi: 10.1016/j.cjca.2016.08.010
44. Badreldin, HA, Atallah B. Global drug shortages due to covid-19: impact on patient care and mitigation strategies. Res Soc Adm
Pharm 2021; 17:1946–1949. https:// doi: 10.1016/j.sapharm.2020.05.017
45. Ideau M, Lebel D, Bussières J.-F. Drug Shortages in Canada: Data for 2016–2017 and perspectives on the problem. Ann pharm
fr. 2019; 77(3): 205–211. https:// doi: 10.1016/j.pharma.2018.11.007
46. Ravela R, Lyles A, Airaksinen M. National and transnational drug shortages: a quantitative descriptive study of public registers
in Europe and the USA. BMC Health Serv Res. 2022; 22(1):1-10 https:// doi: 10.1186/s12913-022-08309-3
47. Claus B, Pauwels K, Baert M, Depoorter J, Weerdt ED, Boussery K. Drug shortages in the hospital: management, causes and
budget impact. J Pharm Belg. 2015;1:24–34 https://pubmed.ncbi.nlm.nih.gov/26571794/
48. Becker DJ, Talwar S, Levy BP, Thorn M, Roitman J, Blum RH. Impact of oncology drug shortages on patient therapy: unplanned
treatment changes. J Oncol Pract. 2013;9:122–8 https:// doi: 10.1200/JOP.2012.000799
49. Gundlapalli AV, Beekmann SE, Graham DR, Polgreen PM. Infectious diseases society of america’s emerging IN. Perspectives
and concerns regarding antimicrobial agent shortages among infectious disease specialists. Diagn Microbiol Infect Dis.
2013;75:256–9. https:// doi: 10.1016/j.diagmicrobio.2012.11.020
50. Lukmanji S, Sauro KM, Josephson CB, Altura KC, Wiebe S, Jetté N. A longitudinal cohort study on the impact of the clobazam
shortage on patients with epilepsy. Epilepsia. 2018;59:468–78. https:// doi: 10.1111/epi.13974
51. Dranitsaris G, Jacobs I, Kirchhoff C, Popovian R, Shane LG. Drug tendering: drug supply and shortage implications for the
uptake of biosimilars. Clinicoecon Outcomes Res. 2017; 9: 573–584. https:// doi: 10.2147/CEOR.S140063
52. Schweitzer SO. How the US food and drug administration can solve the prescription drug shortage problem. Am J Public
Health, 2013; 103 (5): 10-14. https:// doi: 10.2105/AJPH.2013.301239
53. Herath H, Ranaweera K, Rodrigo E. Procurement monitoring and coordination through Information Technology to overcome
drug shortage in the health sector. Sri Lanka J Biomed. Inform, 2011; 12:1-12 http://dx.doi.org/10.4038/sljbmi.v1i0.3554
54. Benhabib A, Ioughlissen S, Ratignier-Carbonneil C, Maison P. The French reporting system for drug shortages: description
and trends from 2012 to 2018: an observational retrospective study. BMJ Open. 2020;10:1-12 https:// doi: 10.1136/
bmjopen-2019-034033
55. Miljković N, Gibbons N, Batista A, Fitzpatrick RW, Underhill J, Horák P. Results of EAHP’s 2018 Survey on Medicines Shortages.
Eur J Hosp Pharm. 2019;26:60. https:// doi: 10.1136/ejhpharm-2018-001835
56. Miljković N, Batista A, Polidori P, Kohl S, Horák P. Results of EAHP’s 2019 Medicines Shortages Survey. Eur J Hosp Pharm Sci
Pract. 2020;27:202–8. https://doi: 10.1136/ejhpharm-2020-002341.
57. Bochenek T, Abilova V, Alkan A, Asanin B, Beriain I d M, Besovic Z. Systemic measures and legislative and organizational
frameworks aimed at preventing or mitigating drug shortages in 28 European and western Asian countries. Front Pharmacol.
2018;8:1-12. https://doi: 10.3389/fphar.2017.00942
58. Vogler S, Fischer S. How to address medicines shortages: Findings from a cross-sectional study of 24 countries. Health Policy.
2020;124 (12) 1287-1296 https://doi.org/10.1016/j.healthpol.2020.09.001
59. Pauwels K, Huys I, Casteels M, Simoens S. Drug shortages in European countries: a trade-off between market attractiveness
and cost containment? BMC Health Serv Res. 2014;14:1-14. https:// doi: 10.1186/1472-6963-14-438.
60. Cameron EE, Bushell M-JA. Analysis of drug shortages across two countries during pre-pandemic and pandemic times. Res Soc
Adm Pharm. 2021;17:1570–3 https://doi: 10.1016/j.sapharm.2020.12.001.
61. Woodcock J, Wosinska M. Economic and technological drivers of generic sterile injectable drug shortages. Clin Pharmacol Ther.
2013;93:170–6. https://doi: 10.1038/clpt.2012.220.
62. Costelloe, E. An audit of drug shortages in a community pharmacy practice. Irish J Med Sci, 2015;184(2): 435-440. https://doi:10.1007/s11845-014-1139-7
63. De Weerdt E, Simoens S, Hombroeckx L, Casteels M, Huys I . Causes of drug shortages in the legal pharmaceutical framework.
Regul Toxicol Pharmacol 2015;71 (2): 251-258 https:// doi: 10.1016/j.yrtph.2015.01.005
64. Emmett D. Supply chains in healthcare organizations: lessons learned from recent shortages. Hosp. Top; 2019. 97: 133–138
https:// doi: 10.1080/00185868.2019.1644264
65. Mazer-Amirshahi M, Fox ER, Zocchi MS, Pines JM, van den Anker JN. Longitudinal trends in U.S. shortages of sterile solutions,
2001-17. Am J Health Syst Pharm. 2018;75(23):1903-1908. https:// doi: 10.2146/ajhp180203
66. Yagnik KJ , Brown LS, Saad HA , Alvarez K. Implementation of IV push antibiotics for outpatients during a national fluid shortage
following Hurricane Maria. Open Forum Infect Dis.2022;9(5): 117-122. https:// doi: 10.1093/ofid/ofac117
67. Nystrom EM, Bergquist WJ, Wieruszewski PM. Parenteral nutrition drug shortages: A single-center experience with rapid
process change. JPEN J Parenter Enteral Nutr. 2019; 43(5): 583-590. https:// doi: 10.1002/jpen.1538
68. Melin K , Rodríguez-Díaz CE. Community pharmacy response in the aftermath of natural disasters: time-sensitive opportunity
for research and evaluation. J Prim Care Community Health . 2018;9: 1-11 https://doi: 10.1177/2150132718813494
69. Marin MLM , Oliveira BBC, Cipriano SL. Oseltamivir compounding in the hospital pharmacy during the (H1N1) influenza
pandemic. Clinics (Sao Paulo) . 2010; 65(11):1081-6. https:// doi: 10.1590/s1807-59322010001100004.
70. Hui DS, Lee N, Chan PKS. Clinical management of pandemic 2009 influenza A(H1N1) infection. Chest. 2010;137(4):916-25.
https:// doi: 10.1378/chest.09-2344
71. Butterfield L, Cash J, Pham K. Drug Shortages and Implications for Pediatric Patients. J Pediatr Pharmacol Ther. 2015; 20(2):
149–152 https:// doi: 10.5863/1551-6776-20.2.149
72. Pisani E, Nistor A-L, Hasnida A, Parmaksiz K, Xu J, Kok MO. Identifying market risk for substandard and falsified medicines: an
analytic framework based on qualitative research in China, Indonesia. Turkey and Romania. Wellcome Open Res. 2019;4:1-7.
https:// doi: 10.12688/wellcomeopenres.15236.1
73. Huff-Rousselle M. The logical underpinnings and benefits of pooled pharmaceutical procurement: a pragmatic role for our
public institutions? Soc Sci Med. 2012;75:1572–80. https:// doi: 10.1016/j.socscimed.2012.05.044
74. DeRoeck D, Bawazir SA, Carrasco P, Kaddar M, Brooks A, Fitzsimmons J. Regional group purchasing of vaccines: review of the
Pan American health organization EPI revolving fund and the Gulf cooperation council group purchasing program. Int J Health
Plann Manag. 2006;21:23–43. https:// doi: 10.1002/hpm.822.
75. Wirtz VJ, Hogerzeil HV, Gray AL, Bigdeli M, de JCP, Ewen MA. Essential medicines for universal health coverage. Lancet.
2017;389:403–76 https:// doi: 10.1016/S0140-6736(16)31599-9
76. McEvoy E, Ferri D. The role of the joint procurement agreement during the COVID-19 pandemic: assessing its usefulness and
discussing its potential to support a European health union. Eur J Risk Regul. 2020;11:851–63 https://www.cambridge.org/
core/journals/european-journal-of-risk-regulation/article/abs/role-of-the-joint-procurement-agreement-during-the-covid19-
pandemic-assessing-its-usefulness-and-discussing-its-potential-to-support-a-european-health-union/962A64946053159BEF
68F24CF26E5142
77. Ripin DJ, Jamieson D, Meyers A, Warty U, Dain M, Khamsi C. Antiretroviral procurement and supply chain management. Antivir
Ther. 2014;19:79–89 https://doi: 10.3851/IMP2903
78. Roy V. A way to low cost, quality medicines: implementation of an essential medicines policy in public health facilities in Delhi
(India). Int J Res Pharm Sci. 2013;4:397–410. https://ijrps.com/home/article/view/3729
79. Lega F, Marsilio M, Villa S. An evaluation framework for measuring supply chain performance in the public healthcare sector:
evidence from the Italian NHS. Prod Plan Control. 2013;24:931–47. https://doi.org/10.1080/09537287.2012.666906
80. Singh PV, Tatambhotla A, Kalvakuntla R, Chokshi M. Understanding public drug procurement in India: a comparative qualitative
study of five Indian states. BMJ Open. 2013;3:1-10 https://doi: 10.1136/bmjopen-2012-001987
81. Kim SW, Skordis-Worrall J. Can voluntary pooled procurement reduce the price of antiretroviral drugs? A case study of Efavirenz.
Health Policy Plan. 2017;32:516–26. https:// doi: 10.1093/heapol/czw165
82. Moye-Holz D, Dreser A, van Dijk JP, Reijneveld SA, Hogerzeil HV. Access to cancer medication in public hospitals in a middleincome
country: the view of stakeholder. Res Soc Adm Pharm. 2020;16:1255–63. https:// doi: 10.1016/j.sapharm.2019.11.015
83. De Oliveira LH, Danovaro-Holliday MC, Sanwogou NJ, Ruiz-Matus C, Tambini G, Andrus JK. Progress in the introduction of the
rotavirus vaccine in Latin America and the Caribbean: four years of accumulated experience. J Pediatr Infect Dis. 2011;30:S61–
6. https:// doi: 10.1097/INF.0b013e3181fefdd6
84. Baldi S, Vannoni D. The impact of centralization on pharmaceutical procurement prices: the role of institutional quality and
corruption. Reg Stud. 2017;51:426–38. https://doi.org/10.1080/00343404.2015.1101517
85. Chen L, Yang Y, Luo M, Hu B, Yin S, Mao Z. The impacts of national centralized drug procurement policy on drug utilization
and drug expenditures: the case of Shenzhen, China. Int J Environ Res Public Health. 2020;17:1–11 https:// doi: 10.3390/
ijerph17249415
86. Perez AV, Trujillo AJ, Mejia AE, Contreras JD, Sharfstein JM. Evaluating the centralized purchasing policy for the treatment of
hepatitis C: the Colombian CASE. Pharmacol Res Perspect. 2019;7:1-10 https:// doi: 10.1002/prp2.552
87. Wafula F, Agweyu A, Macintyre K. Regional and temporal trends in malaria commodity costs: an analysis of Global Fund data
for 79 countries. Malar J. 2013;12 https:// doi: 10.1186/1475-2875-12-466 88. Cowan AE, Clark SJ, Gordon JL, Bok K, Shen AK. Vaccine purchasing groups in the United States: an overview of their policies
and practices. Vaccine. 2016;34:5060–5. https:// doi: 10.1016/j.vaccine.2016.08.080
89. Shi J, Liu R, Jiang H, Wang C, Xiao Y, Liu N. Moving towards a better path? A mixed-method examination of China’s reforms to
remedy medical corruption from pharmaceutical firms. BMJ Open. 2018;8:1-12. https://doi: 10.1136/bmjopen-2017-018513
90. Dubois P, Lefouili Y, Straub S. Pooled procurement of drugs in low and middle income countries. Eur Econ Rev. 2021;132:1-14
https://www.cgdev.org/sites/default/files/pooled-procurement-drugs-low-and-middle-income-countries.pdf
91. Qendri V, Bogaards JA, Berkhof J. Pricing of HPV vaccines in European tender-based settings. Eur J Health Econ. 2019;20:271–
80. https:// doi: 10.1007/s10198-018-0996-9
92. Sruamsiri R, Ross-Degnan D, Lu CY, Chaiyakunapruk N, Wagner AK. Policies and programs to facilitate access to targeted cancer
therapies in Thailand. PLoS One. 2015;10:1-13 https:// doi: 10.1371/journal.pone.0119945.
93. Bissell K, Perrin C, Beran D. Access to essential medicines to treat chronic respiratory disease in low-income countries. Int J
Tuberc Lung Dis. 2016;20:717–28. https:// doi: 10.5588/ijtld.15.0734
94. Blankart KE, Felder S. Do medicine shortages reduce access and increase pharmaceutical expenditure? A retrospective analysis
of Switzerland 2015-2020. Value Health. 2022;25 (7): 1124-1132 https:// doi: 10.1016/j.jval.2021.12.017
95. Romano S, Guerreiro JP, Rodrigues AT. Drug shortages in community pharmacies: Impact on patients and on the health system.
J Am Pharm Assoc. 2022; 62 (3): 791-799. https://pubmed.ncbi.nlm.nih.gov/35115262/
96. Ahmad F, Alnowibet KA, Alrasheedi AF, Adhami AY. A multi-objective model for optimizing the socio-economic performance of
a pharmaceutical supply chain. Socio-Econ. Plan Sci. 2022;79:1-22 https://doi.org/10.1016/j.seps.2021.101126
97. Pauwels K, Simoens S, Casteels M, Huys I Insights into European drug shortages: A survey of hospital pharmacists. PLoS One.
2015; 10(3): 1-12 https://doi: 10.1371/journal.pone.0119322
98. Alyami HS, Naser AY, Alyami MH. Drug shortages in Najran region, Saudi Arabia: A cross-sectional survey. Clin Epidemiol Glob
Health.2023; 21: 1-12 https://doi.org/10.1016/j.cegh.2023.101305
99. AlRuthia Y, Almutiri NM, Almutairi RM. Local causes of essential medicines shortages from the perspective of supply chain
professionals in Saudi Arabia. Saudi Pharma J. 2023; 31(6): 948-954. https:// doi: 10.1016/j.jsps.2023.04.019
100. Alshehri S, Alshammari R, Alyamani M. Current and future prospective of pharmaceutical manufacturing in Saudi Arabia.
Saudi Pharma J. 2023; 31(4): 605-616 https:// doi: 10.1016/j.jsps.2023.03.001
101. Alsheikh MY, Alzahrani MA , Alsharif NA. Community Pharmacy Staff Knowledge, Opinion and Practice toward Drug Shortages
in Saudi Arabia. Saudi Pharma J. 2021; 29(12): 1383-1391 https:// doi: 10.1016/j.jsps.2021.09.001
102. Bouvy F, and Rotaru M. Medicine shortages: from assumption to evidence to action-a proposal for using the FMD data
repositories for shortages monitoring. Front Med. 2021; 8:1-12 https:// doi: 10.3389/fmed.2021.579822
103. Koenraadt R, Van De Ven K. The internet and lifestyle drugs: an analysis of demographic characteristics, methods, and motives
of online purchasers of illicit lifestyle drugs in the Netherlands. Drugs Educ Prev Pol 2018;25: 345–355 https://doi.org/10.10
80/09687637.2017.1369936
104. Shuman A, Unguru Y. Drug Shortages: The View Across an Ocean. Oncologist. 2020 ;25(4):274-276. https:// doi: 10.1634/
theoncologist.2019-1010
105. Clark SL, Levasseur-Franklin K, Pajoumand M, Barra M, Armahizer M, Patel DV, Wyatt Chester K, Tully AP. Collaborative
management strategies for drug shortages in neurocritical care. Neurocrit Care. 2020;32(1):226-237 https:// doi: 10.1007/
s12028-019-00730-7
106. Decamp M, Joffe S, Fernandez CV, Faden RR, Unguru Y. Working group on chemotherapy drug shortages in pediatric oncology.
chemotherapy drug shortages in pediatric oncology: a consensus statement. Pediatrics. 2014;133(3): 716-24 https://doi:
10.1542/peds.2013-2946
107. Donnelly KA, Zocchi MS, Katy TA, Fox ER, Pines JM, van den Anker JN, Mazer-Amirshahi ME. Prescription Drug Shortages:
Pediatric Emergency and Critical Care Medications. Pediatr Emerg Care. 2021 1;37(11): 726-731 https:// doi: 10.1097/
PEC.0000000000001773
108. Li E, Subramanian J, Anderson S, Thomas D, McKinley J, Jacobs IA. Development of biosimilars in an era of oncologic drug
shortages. Drug Des Devel Ther. 2015 24;9:3247-55. https:// doi: 10.2147/DDDT.S75219
109. Pall R, Gauthier Y, Auer S, Mowaswes W. Predicting drug shortages using pharmacy data and machine learning. Health Care
Manag Sci. 2023; 13:1–17. https:// doi: 10.1007/s10729-022-09627-y
110. Cantrell Lee. Stability of active ingredients in long-expired prescription medications. Arch Intern Med. 2012;172(21):1685–
1687 https:// doi: 10.1001/archinternmed.2012.4501
111. Jasinska M, Karwowski B, Orszulak-Michalak D, Kurczewska U. Stability studies of expired tablets of metoprolol tartrate and
propranolol hydrochloride. Part 1. Content determination, Acta Pol Pharm 66 (2009): 697–701 https://pubmed.ncbi.nlm.nih.
gov/20050534/
112. Sharma S, Sharma AK, Moe HW, Khanapure A, Mohan P. A study to investigate the chemical potency, physical stability, and
efficacy of analgesic agents over a period of two years post their expiry date. Med J Armed Forces India. 2022;78(Suppl
1):S194-S200. doi: 10.1016/j.mjafi.2021.03.015
113. Diven D.G., Bartenstein D.W., Carroll D.R. Extending Shelf Life Just Makes Sense. Mayo Clin Proc. 2015;90(11):1471–1474. doi:
10.1016/j.mayocp.2015.08.007 114. Acosta A., Vanegas E.P., Rovira J., Godman B., Bochenek T. Medicine shortages: gaps between countries and global perspectives.
Front Pharmacol. 2019;10 doi: 10.3389/fphar.2019.00763
115. Giammona R, Di-Martino E, Vinci DL, Provenzani, A, and Polidori, P. Hazard vulnerability analysis to evaluate the risk of drug
shortages according to therapeutic class. Br Med J.2020; 116:1–16. https://ejhp.bmj.com/content/ejhpharm/27/Suppl_1/
A194.1.full.pdf
116. Haider A, Qian Y, Lu Z, Naqvi S, Zhuang A, Reddy A. Implications of the parenteral opioid shortage for prescription patterns and
pain control among hospitalized patients with cancer referred to palliative care. JAMA Oncol 2019; 5: 841–846. https:// doi:
10.1001/jamaoncol.2019.0062
117. Rhodes NJ, Gilbert EM, Skoglund E, Esterly JS, Postelnick MJ, Mclaughlin MM. Prediction of inventory sustainability during a
drug shortage. Am J Health-System Pharm. 2016; 73: 1094–1098 https:// doi: 10.2146/ajhp150532
118. Modisakeng C, Matlala M, Godman B, Meyer JC. Medicine shortages and challenges with the procurement process among
public sector hospitals in South Africa; Findings and implications. BMC Health Serv Res. 2020; 20:1–10. https:// doi: 10.1186/
s12913-020-05080-1
119. Lyon J. Drug shortage compounding: the only safe medication source in a time of crisis. Int J Pharm compounding 2012;16:
456–460 https://pubmed.ncbi.nlm.nih.gov/23259360/
120. Meng M, Lv M, Wang L, Yang B, Jiao P, Lei W, Lan H, Shen Q, Luo X, Zhou Q, Yu X, Xun Y, Lei R, Hou T, Chen Y, Li Q. Off-label use
of drugs in pediatrics: a scoping review. Eur J Pediatr. 2022;181(9):3259-3269. doi: 10.1007/s00431-022-04515-7
121. Ekedahl ABE. Reasons why medicines are returned to Swedish pharmacies unused. Pharm. World Sci. 2007;28:352–358.
https://doi: 10.1007/s11096-006-9055-1
122. Lee BK, Ellenbecker MJ, Moure-Ersaso R. Alternatives for treatment and disposal cost reduction of regulated medical wastes.
Waste Manag. 2004; 24(2):143-51. doi: 10.1016/j.wasman.2003.10.008
123. Makki M, Hassali MA, Awaisu A, Hashmi F. The Prevalence of Unused Medications in Homes. Pharmacy (Basel). 2019,
13;7(2):61. doi: 10.3390/pharmacy7020061
124. Smale EM, Egberts TCG, Heerdink ER. Waste-minimising measures to achieve sustainable supply and use of medication.
Sustain Chem Pharm, 2021 ; 21: 1-14 https://doi.org/10.1016/j.scp.2021.100400
review. PLoS One . 2019;14(5): 1-12. https://doi.org/10.1371/journal.pone.0215837
2. Atif M, Sehar A, Malik I, Mushtaq I, Ahmad N, Babar ZU. What impact does medicines shortages have on patients? A qualitative
study exploring patients’ experience and views of healthcare professionals. BMC Health Serv Res. 2021;21(1): 1-10. https://
doi: 10.1186/s12913-021-06812-7.
3. Hedman L. Global approaches to addressing shortages of essential medicines in health systems. WHO Drug Information. 2016;
30(2):180–185. https://iris.who.int/handle/10665/331028
4. Omer S, Pan M , Ali S, Shukar S , Fang Y, Yang C. Perceptions of pharmacists towards drug shortages in the healthcare system
of Pakistan and its impact on patient care: findings from a cross-sectional survey. BMJ Open. 2021;11(12): 1-11. https://doi:
10.1136/bmjopen-2021-050196.
5. Tan YX, Moles RJ, Chaar BB. Medicine shortages in Australia: causes, impact and management strategies in the community
setting. Int J Clin Pharm. 2016; 38(5):1133–41. https://doi: 10.1007/s11096-016-0342-1
6. Thoma BN, Li J, McDaniel CM, Wordell CJ, Cavarocchi N, Pizzi LT. Clinical and economic impact of substituting dexmedetomidine
for propofol due to a US drug shortage: Examination of coronary artery bypass graft patients at an urban medical centre.
PharmacoEconomics. 2014; 32(2):149–57. https://doi:10.1007/s11096-020-01103-3
7. Al Ruthia YS, Al Kofide H, Al Ajmi R, Balkhi B, Alghamdi A, Al Nasser A. Drug shortages in large hospitals in Riyadh: A cross- sectional study. Ann Saudi Med. 2017; 37(5):375–85. https://doi:doi: 10.5144/0256-4947.2017.375.
8. Dill S, Ahn J. Drug Shortages in developed countries-reasons, therapeutic consequences, and handling. Eur J Clin Pharmacol.
2014;70: 1405–1412 https://doi: 10.1007/s00228-014-1747-1
9. McLaughlin M, Kotis D, Thomson K, Harrison M, Fennessy G, Postelnick M. Effects on patient care caused by drug shortages: A
survey. J Manag Care Pharm. 2013; 19(9):783–8 https://doi: 10.18553/jmcp.2013.19.9.783
10. Souliotis K, Papageorgiou M, Politi A, Ioakeimidis D, Sidiropoulos P. Barriers to accessing biologic treatment for rheumatoid
arthritis in Greece: The unseen impact of the fiscal crisis—The Health Outcomes Patient Environment (HOPE) study. Rheumatol
Int. 2014; 34(1):25–33 https:// doi: 10.1007/s00296-013-2866-1
11. Atif M, Malik I, Mushtaq I, Asghar S. Medicines shortages in Pakistan: a qualitative study to explore current situation, reasons
and possible solutions to overcome the barriers. BMJ Open. 2019;9(9): 1-10 https:// doi: 10.1136/bmjopen-2018-027028.
12. Ventola CL. The Drug shortage crisis in the United States: causes, impact, and management strategies. Pharm Ther. 2011;36:
740-8 https://pubmed.ncbi.nlm.nih.gov/22346307
13. Shukar S, Zahoor F, Hayat K, Saeed A, Gillani AH, Omer S, Hu S, Babar ZU, Fang Y, Yang C. Drug shortage: causes, impact, and
mitigation strategies. Front Pharmacol. 2021;9: 1-12 https://doi.org/10.3389/fphar.2021.693426
14. Videau M, Chemali L, Stucki C, Saavedra-Mitjans M, Largana S, Guerin, A. Drug Shortages in Canada and Selected European
Countries: a Cross-Sectional, Institution-Level Comparison. Can J Hosp Pharm.2019; 72: 1-7 https://pubmed.ncbi.nlm.nih.
gov/30828089
15. Wall S, Bangalee V. The Ketamine Crisis: Does South Africa Have a Plan B?. S Afr Med J. 2019;109: 911–913. https://doi:
10.7196/SAMJ.2019.v109i12.14188
16. Pava MLSDL, Tucker EL. Drug shortages in low- and middle-income countries: Colombia as a case study. J Pharm Policy Pract.
2022;15(1):1-4 https:// doi: 10.1186/s40545-022-00439-7
17. Khan FA. Anesthetic drugs shortage in lower and middle income countries: a safety and quality issue. Anaesth Pain Intensive
Care. 2019; 23(4): 337–339. https://www.apicareonline.com/index.php/APIC/article/view/1164/1949
18. Yang C, Wu L, Cai W, Zhu W, Shen Q, Li Z. Current situation, determinants, and solutions to drug shortages in Shaanxi province,
China: A qualitative study. PloS One. 2016; 11:1-11 https:// doi: 10.1371/journal.pone.0165183
19. Mazer-Amirshahi M, Pourmand A, Singer S, Pines JM, Anker J. Critical drug shortages: implications for emergency medicine.
Acad Emerg Med. 2014;21(6):704-11 https:// doi: 10.1111/acem.12389
20. Schwartzberg E, Ainbinder D, Vishkauzan A, Gamzu R. Drug shortages in Israel: regulatory perspectives, challenges and
solutions. Isr J Health Policy Res. 2017; 6(1): 1-7. https:// doi: 10.1186/s13584-017-0140-9
21. Awad H, Al-Zu’bi MF, Abdallah AB. A quantitative analysis of the causes of drug shortages in Jordan: a supply chain perspective.
Int J Bus Res. 2016; 9(6):1-11 https://www.ccsenet.org/journal/index.php/ibr/article/view/57405
22. Walker J, Chaar BB, Vera N, Pillai AS, Lim JS, Bero L, Moles RJ. Medicine shortages in Fiji: A qualitative exploration of stakeholders’
views. PLoS One.2017 ;12(6): 1-12 https:// doi: 10.1371/journal.pone.0178429
23. Alruthia YS. Alwhaibi M, Alotaibi MF. Drug shortages in Saudi Arabia: Root causes and recommendations. Saudi Pharm J, 2018.
26(7): p. 947-951 https:// doi: 10.1016/j.jsps.2018.05.002
24. Meloni ST, Chaplin B, Idoko J. Drug resistance patterns following pharmacy stock shortage in Nigerian Antiretroviral Treatment
Program. AIDS Res Ther. 2017;14(1):1-8. https://doi: 10.1186/s12981-017-0184-5.
25. Videau M, Lebel D, Bussière JF. Drug shortages in Canada: Data for 2016-2017 and perspectives on the problem. Ann Pharm
Fr. 2019;77(3): 205-211 https:// doi: 10.1016/j.pharma.2018.11.007
26. Alsheikh M, Seoane-Vazquez E, Rittenhouse B. A comparison of drug shortages in the hospital setting in the United States and
Saudi Arabia: An exploratory analysis. Hosp Pharm. 2016; 51(5): 370-5 https:// doi: 10.1310/hpj5105-370
27. Malik M, Hassali MA, Shafie AA, Hussain A. Why hospital pharmacists have failed to manage anti-malarial drugs stock-outs in
Pakistan? A qualitative insight. Malar Res Treat. 2013; 13:1-14 https:// doi: 10.1155/2013/342843
28. Heiskanen K, Ahonen R, Kanerva R, Karttunen P, Timonen J. The reasons behind medicine shortages from the perspective of
pharmaceutical companies and pharmaceutical wholesalers in Finland. PLoS One.2017; 12(6): 1-12 https:// doi: 10.1371/
journal.pone.0179479
29. Fatima SA, Khaliq A. A survey regarding drug shortage in tertiary care hospitals of Karachi, Pakistan. J Pharm Pract Community
Med. 2017; 3:262–266. https:// doi:10.5530/jppcm.2017.4.69
30. McBride A, Holle LM, Westendorf C, Sidebottom M, Griffith N, Muller RJ, Hoffman JM. National survey on the effect of oncology
drug shortages on cancer care. Am J Health Syst Pharm. 70 (7):609–617. https:// doi: 10.2146/ajhp120563
31. Barthelemy I, Bussières JF, Bourdon O. Drug shortages and antimicrobial agents: a cross-sectional France-Canada comparison
and perspective. European Society of Clinical Pharmacy, Leuven, Belgique. Int J Clin Pharm 2012;34(5):779-94 https://indicible.
ca/urpp/20120522_RUPTURES6_Affiche.pdf
32. Wiggins BS, Nappi J, Fortier CR, Taber DJ. Cardiovascular drug shortages: Predominant etiologies, clinical implications, and
management strategies. Ann Pharmacother 2014; 48(9):1177-1186 https://doi: 10.1177/1060028014539142
33. Dave CV, Pawar A, Fox ER, Brill G, Kesselheim AS. Predictors of drug shortages and association with generic drug prices: A
retrospective cohort study. Value health. 2018 21(11):1286-1290. https:// doi: 10.1016/j.jval.2018.04.1826
34. McKenna M. Hospital pharmacists scrambling amid vast drug shortages: Emergency physicians between rock and hard place. Ann Emerg Med. 2011; 57(2):13–15. https:// doi: 10.1016/j.annemergmed.2010.12.006
35. Johnson TJ. Drug shortages: An increasing problem for patients and clinicians. S D Med. 2011; 64(1):14–15 https://pubmed.
ncbi.nlm.nih.gov/21337920
36. Kaakeh R, Sweet B, Reilly C. Impact of drug shortages on U.S. health systems. Am J Health Syst Pharm. 2011;68:1811–1819.
https:// doi: 10.2146/ajhp110210.
37. Jenks S. Efforts underway to curb drug shortages. J Natl Cancer Inst. 2011;103(12):914–915. https:// doi: 10.1093/jnci/djr234
38. Thompson C. House legislation proposes early warning system for drug shortages. Am J Health Syst Pharm. 2011;68:1379–
1381. https:// doi: 10.2146/news110052
39. Thompson C. Stakeholders in supply chain discuss shortages. Am J Health Syst Pharm. 2011; 68: 9–10 https:// doi: 10.2146/
news100088
40. Cummings MJ, Baldwin MR, Abrams D. Epidemiology, clinical course and outcomes of critically ill adults with COVID-19 in New
York City: a prospective cohort study. Lancet. 2020; 395: 1763-1770 https:// doi: 10.1016/S0140-6736(20)31189-2
41. Mori J, Hasui K, Tanimoto T, Matsumura T, Kami M. Drug Shortages After the Eastern Japan Earthquake: Experiences in a
Tertiary Referral Center. Drug Inf J. 2012;46(5):607–10 https://link.springer.com/article/10.1177/0092861512448569
42. Ayati N, Saiyarsarai P, Nikfar S. Short and Long Term Impacts of COVID-19 on the Pharmaceutical Sector. DARU J Pharm Sci
2020;28:799–805. https:// doi: 10.1007/s40199-020-00358-5
43. Rinaldi, F., de Denus, S., Nguyen, A., Nattel, S., & Bussières, J.-F. Drug shortages: patients and health care providers are all
drawing the short straw. Can J Cardiol, 2017;33(2): 283–286 https:// doi: 10.1016/j.cjca.2016.08.010
44. Badreldin, HA, Atallah B. Global drug shortages due to covid-19: impact on patient care and mitigation strategies. Res Soc Adm
Pharm 2021; 17:1946–1949. https:// doi: 10.1016/j.sapharm.2020.05.017
45. Ideau M, Lebel D, Bussières J.-F. Drug Shortages in Canada: Data for 2016–2017 and perspectives on the problem. Ann pharm
fr. 2019; 77(3): 205–211. https:// doi: 10.1016/j.pharma.2018.11.007
46. Ravela R, Lyles A, Airaksinen M. National and transnational drug shortages: a quantitative descriptive study of public registers
in Europe and the USA. BMC Health Serv Res. 2022; 22(1):1-10 https:// doi: 10.1186/s12913-022-08309-3
47. Claus B, Pauwels K, Baert M, Depoorter J, Weerdt ED, Boussery K. Drug shortages in the hospital: management, causes and
budget impact. J Pharm Belg. 2015;1:24–34 https://pubmed.ncbi.nlm.nih.gov/26571794/
48. Becker DJ, Talwar S, Levy BP, Thorn M, Roitman J, Blum RH. Impact of oncology drug shortages on patient therapy: unplanned
treatment changes. J Oncol Pract. 2013;9:122–8 https:// doi: 10.1200/JOP.2012.000799
49. Gundlapalli AV, Beekmann SE, Graham DR, Polgreen PM. Infectious diseases society of america’s emerging IN. Perspectives
and concerns regarding antimicrobial agent shortages among infectious disease specialists. Diagn Microbiol Infect Dis.
2013;75:256–9. https:// doi: 10.1016/j.diagmicrobio.2012.11.020
50. Lukmanji S, Sauro KM, Josephson CB, Altura KC, Wiebe S, Jetté N. A longitudinal cohort study on the impact of the clobazam
shortage on patients with epilepsy. Epilepsia. 2018;59:468–78. https:// doi: 10.1111/epi.13974
51. Dranitsaris G, Jacobs I, Kirchhoff C, Popovian R, Shane LG. Drug tendering: drug supply and shortage implications for the
uptake of biosimilars. Clinicoecon Outcomes Res. 2017; 9: 573–584. https:// doi: 10.2147/CEOR.S140063
52. Schweitzer SO. How the US food and drug administration can solve the prescription drug shortage problem. Am J Public
Health, 2013; 103 (5): 10-14. https:// doi: 10.2105/AJPH.2013.301239
53. Herath H, Ranaweera K, Rodrigo E. Procurement monitoring and coordination through Information Technology to overcome
drug shortage in the health sector. Sri Lanka J Biomed. Inform, 2011; 12:1-12 http://dx.doi.org/10.4038/sljbmi.v1i0.3554
54. Benhabib A, Ioughlissen S, Ratignier-Carbonneil C, Maison P. The French reporting system for drug shortages: description
and trends from 2012 to 2018: an observational retrospective study. BMJ Open. 2020;10:1-12 https:// doi: 10.1136/
bmjopen-2019-034033
55. Miljković N, Gibbons N, Batista A, Fitzpatrick RW, Underhill J, Horák P. Results of EAHP’s 2018 Survey on Medicines Shortages.
Eur J Hosp Pharm. 2019;26:60. https:// doi: 10.1136/ejhpharm-2018-001835
56. Miljković N, Batista A, Polidori P, Kohl S, Horák P. Results of EAHP’s 2019 Medicines Shortages Survey. Eur J Hosp Pharm Sci
Pract. 2020;27:202–8. https://doi: 10.1136/ejhpharm-2020-002341.
57. Bochenek T, Abilova V, Alkan A, Asanin B, Beriain I d M, Besovic Z. Systemic measures and legislative and organizational
frameworks aimed at preventing or mitigating drug shortages in 28 European and western Asian countries. Front Pharmacol.
2018;8:1-12. https://doi: 10.3389/fphar.2017.00942
58. Vogler S, Fischer S. How to address medicines shortages: Findings from a cross-sectional study of 24 countries. Health Policy.
2020;124 (12) 1287-1296 https://doi.org/10.1016/j.healthpol.2020.09.001
59. Pauwels K, Huys I, Casteels M, Simoens S. Drug shortages in European countries: a trade-off between market attractiveness
and cost containment? BMC Health Serv Res. 2014;14:1-14. https:// doi: 10.1186/1472-6963-14-438.
60. Cameron EE, Bushell M-JA. Analysis of drug shortages across two countries during pre-pandemic and pandemic times. Res Soc
Adm Pharm. 2021;17:1570–3 https://doi: 10.1016/j.sapharm.2020.12.001.
61. Woodcock J, Wosinska M. Economic and technological drivers of generic sterile injectable drug shortages. Clin Pharmacol Ther.
2013;93:170–6. https://doi: 10.1038/clpt.2012.220.
62. Costelloe, E. An audit of drug shortages in a community pharmacy practice. Irish J Med Sci, 2015;184(2): 435-440. https://doi:10.1007/s11845-014-1139-7
63. De Weerdt E, Simoens S, Hombroeckx L, Casteels M, Huys I . Causes of drug shortages in the legal pharmaceutical framework.
Regul Toxicol Pharmacol 2015;71 (2): 251-258 https:// doi: 10.1016/j.yrtph.2015.01.005
64. Emmett D. Supply chains in healthcare organizations: lessons learned from recent shortages. Hosp. Top; 2019. 97: 133–138
https:// doi: 10.1080/00185868.2019.1644264
65. Mazer-Amirshahi M, Fox ER, Zocchi MS, Pines JM, van den Anker JN. Longitudinal trends in U.S. shortages of sterile solutions,
2001-17. Am J Health Syst Pharm. 2018;75(23):1903-1908. https:// doi: 10.2146/ajhp180203
66. Yagnik KJ , Brown LS, Saad HA , Alvarez K. Implementation of IV push antibiotics for outpatients during a national fluid shortage
following Hurricane Maria. Open Forum Infect Dis.2022;9(5): 117-122. https:// doi: 10.1093/ofid/ofac117
67. Nystrom EM, Bergquist WJ, Wieruszewski PM. Parenteral nutrition drug shortages: A single-center experience with rapid
process change. JPEN J Parenter Enteral Nutr. 2019; 43(5): 583-590. https:// doi: 10.1002/jpen.1538
68. Melin K , Rodríguez-Díaz CE. Community pharmacy response in the aftermath of natural disasters: time-sensitive opportunity
for research and evaluation. J Prim Care Community Health . 2018;9: 1-11 https://doi: 10.1177/2150132718813494
69. Marin MLM , Oliveira BBC, Cipriano SL. Oseltamivir compounding in the hospital pharmacy during the (H1N1) influenza
pandemic. Clinics (Sao Paulo) . 2010; 65(11):1081-6. https:// doi: 10.1590/s1807-59322010001100004.
70. Hui DS, Lee N, Chan PKS. Clinical management of pandemic 2009 influenza A(H1N1) infection. Chest. 2010;137(4):916-25.
https:// doi: 10.1378/chest.09-2344
71. Butterfield L, Cash J, Pham K. Drug Shortages and Implications for Pediatric Patients. J Pediatr Pharmacol Ther. 2015; 20(2):
149–152 https:// doi: 10.5863/1551-6776-20.2.149
72. Pisani E, Nistor A-L, Hasnida A, Parmaksiz K, Xu J, Kok MO. Identifying market risk for substandard and falsified medicines: an
analytic framework based on qualitative research in China, Indonesia. Turkey and Romania. Wellcome Open Res. 2019;4:1-7.
https:// doi: 10.12688/wellcomeopenres.15236.1
73. Huff-Rousselle M. The logical underpinnings and benefits of pooled pharmaceutical procurement: a pragmatic role for our
public institutions? Soc Sci Med. 2012;75:1572–80. https:// doi: 10.1016/j.socscimed.2012.05.044
74. DeRoeck D, Bawazir SA, Carrasco P, Kaddar M, Brooks A, Fitzsimmons J. Regional group purchasing of vaccines: review of the
Pan American health organization EPI revolving fund and the Gulf cooperation council group purchasing program. Int J Health
Plann Manag. 2006;21:23–43. https:// doi: 10.1002/hpm.822.
75. Wirtz VJ, Hogerzeil HV, Gray AL, Bigdeli M, de JCP, Ewen MA. Essential medicines for universal health coverage. Lancet.
2017;389:403–76 https:// doi: 10.1016/S0140-6736(16)31599-9
76. McEvoy E, Ferri D. The role of the joint procurement agreement during the COVID-19 pandemic: assessing its usefulness and
discussing its potential to support a European health union. Eur J Risk Regul. 2020;11:851–63 https://www.cambridge.org/
core/journals/european-journal-of-risk-regulation/article/abs/role-of-the-joint-procurement-agreement-during-the-covid19-
pandemic-assessing-its-usefulness-and-discussing-its-potential-to-support-a-european-health-union/962A64946053159BEF
68F24CF26E5142
77. Ripin DJ, Jamieson D, Meyers A, Warty U, Dain M, Khamsi C. Antiretroviral procurement and supply chain management. Antivir
Ther. 2014;19:79–89 https://doi: 10.3851/IMP2903
78. Roy V. A way to low cost, quality medicines: implementation of an essential medicines policy in public health facilities in Delhi
(India). Int J Res Pharm Sci. 2013;4:397–410. https://ijrps.com/home/article/view/3729
79. Lega F, Marsilio M, Villa S. An evaluation framework for measuring supply chain performance in the public healthcare sector:
evidence from the Italian NHS. Prod Plan Control. 2013;24:931–47. https://doi.org/10.1080/09537287.2012.666906
80. Singh PV, Tatambhotla A, Kalvakuntla R, Chokshi M. Understanding public drug procurement in India: a comparative qualitative
study of five Indian states. BMJ Open. 2013;3:1-10 https://doi: 10.1136/bmjopen-2012-001987
81. Kim SW, Skordis-Worrall J. Can voluntary pooled procurement reduce the price of antiretroviral drugs? A case study of Efavirenz.
Health Policy Plan. 2017;32:516–26. https:// doi: 10.1093/heapol/czw165
82. Moye-Holz D, Dreser A, van Dijk JP, Reijneveld SA, Hogerzeil HV. Access to cancer medication in public hospitals in a middleincome
country: the view of stakeholder. Res Soc Adm Pharm. 2020;16:1255–63. https:// doi: 10.1016/j.sapharm.2019.11.015
83. De Oliveira LH, Danovaro-Holliday MC, Sanwogou NJ, Ruiz-Matus C, Tambini G, Andrus JK. Progress in the introduction of the
rotavirus vaccine in Latin America and the Caribbean: four years of accumulated experience. J Pediatr Infect Dis. 2011;30:S61–
6. https:// doi: 10.1097/INF.0b013e3181fefdd6
84. Baldi S, Vannoni D. The impact of centralization on pharmaceutical procurement prices: the role of institutional quality and
corruption. Reg Stud. 2017;51:426–38. https://doi.org/10.1080/00343404.2015.1101517
85. Chen L, Yang Y, Luo M, Hu B, Yin S, Mao Z. The impacts of national centralized drug procurement policy on drug utilization
and drug expenditures: the case of Shenzhen, China. Int J Environ Res Public Health. 2020;17:1–11 https:// doi: 10.3390/
ijerph17249415
86. Perez AV, Trujillo AJ, Mejia AE, Contreras JD, Sharfstein JM. Evaluating the centralized purchasing policy for the treatment of
hepatitis C: the Colombian CASE. Pharmacol Res Perspect. 2019;7:1-10 https:// doi: 10.1002/prp2.552
87. Wafula F, Agweyu A, Macintyre K. Regional and temporal trends in malaria commodity costs: an analysis of Global Fund data
for 79 countries. Malar J. 2013;12 https:// doi: 10.1186/1475-2875-12-466 88. Cowan AE, Clark SJ, Gordon JL, Bok K, Shen AK. Vaccine purchasing groups in the United States: an overview of their policies
and practices. Vaccine. 2016;34:5060–5. https:// doi: 10.1016/j.vaccine.2016.08.080
89. Shi J, Liu R, Jiang H, Wang C, Xiao Y, Liu N. Moving towards a better path? A mixed-method examination of China’s reforms to
remedy medical corruption from pharmaceutical firms. BMJ Open. 2018;8:1-12. https://doi: 10.1136/bmjopen-2017-018513
90. Dubois P, Lefouili Y, Straub S. Pooled procurement of drugs in low and middle income countries. Eur Econ Rev. 2021;132:1-14
https://www.cgdev.org/sites/default/files/pooled-procurement-drugs-low-and-middle-income-countries.pdf
91. Qendri V, Bogaards JA, Berkhof J. Pricing of HPV vaccines in European tender-based settings. Eur J Health Econ. 2019;20:271–
80. https:// doi: 10.1007/s10198-018-0996-9
92. Sruamsiri R, Ross-Degnan D, Lu CY, Chaiyakunapruk N, Wagner AK. Policies and programs to facilitate access to targeted cancer
therapies in Thailand. PLoS One. 2015;10:1-13 https:// doi: 10.1371/journal.pone.0119945.
93. Bissell K, Perrin C, Beran D. Access to essential medicines to treat chronic respiratory disease in low-income countries. Int J
Tuberc Lung Dis. 2016;20:717–28. https:// doi: 10.5588/ijtld.15.0734
94. Blankart KE, Felder S. Do medicine shortages reduce access and increase pharmaceutical expenditure? A retrospective analysis
of Switzerland 2015-2020. Value Health. 2022;25 (7): 1124-1132 https:// doi: 10.1016/j.jval.2021.12.017
95. Romano S, Guerreiro JP, Rodrigues AT. Drug shortages in community pharmacies: Impact on patients and on the health system.
J Am Pharm Assoc. 2022; 62 (3): 791-799. https://pubmed.ncbi.nlm.nih.gov/35115262/
96. Ahmad F, Alnowibet KA, Alrasheedi AF, Adhami AY. A multi-objective model for optimizing the socio-economic performance of
a pharmaceutical supply chain. Socio-Econ. Plan Sci. 2022;79:1-22 https://doi.org/10.1016/j.seps.2021.101126
97. Pauwels K, Simoens S, Casteels M, Huys I Insights into European drug shortages: A survey of hospital pharmacists. PLoS One.
2015; 10(3): 1-12 https://doi: 10.1371/journal.pone.0119322
98. Alyami HS, Naser AY, Alyami MH. Drug shortages in Najran region, Saudi Arabia: A cross-sectional survey. Clin Epidemiol Glob
Health.2023; 21: 1-12 https://doi.org/10.1016/j.cegh.2023.101305
99. AlRuthia Y, Almutiri NM, Almutairi RM. Local causes of essential medicines shortages from the perspective of supply chain
professionals in Saudi Arabia. Saudi Pharma J. 2023; 31(6): 948-954. https:// doi: 10.1016/j.jsps.2023.04.019
100. Alshehri S, Alshammari R, Alyamani M. Current and future prospective of pharmaceutical manufacturing in Saudi Arabia.
Saudi Pharma J. 2023; 31(4): 605-616 https:// doi: 10.1016/j.jsps.2023.03.001
101. Alsheikh MY, Alzahrani MA , Alsharif NA. Community Pharmacy Staff Knowledge, Opinion and Practice toward Drug Shortages
in Saudi Arabia. Saudi Pharma J. 2021; 29(12): 1383-1391 https:// doi: 10.1016/j.jsps.2021.09.001
102. Bouvy F, and Rotaru M. Medicine shortages: from assumption to evidence to action-a proposal for using the FMD data
repositories for shortages monitoring. Front Med. 2021; 8:1-12 https:// doi: 10.3389/fmed.2021.579822
103. Koenraadt R, Van De Ven K. The internet and lifestyle drugs: an analysis of demographic characteristics, methods, and motives
of online purchasers of illicit lifestyle drugs in the Netherlands. Drugs Educ Prev Pol 2018;25: 345–355 https://doi.org/10.10
80/09687637.2017.1369936
104. Shuman A, Unguru Y. Drug Shortages: The View Across an Ocean. Oncologist. 2020 ;25(4):274-276. https:// doi: 10.1634/
theoncologist.2019-1010
105. Clark SL, Levasseur-Franklin K, Pajoumand M, Barra M, Armahizer M, Patel DV, Wyatt Chester K, Tully AP. Collaborative
management strategies for drug shortages in neurocritical care. Neurocrit Care. 2020;32(1):226-237 https:// doi: 10.1007/
s12028-019-00730-7
106. Decamp M, Joffe S, Fernandez CV, Faden RR, Unguru Y. Working group on chemotherapy drug shortages in pediatric oncology.
chemotherapy drug shortages in pediatric oncology: a consensus statement. Pediatrics. 2014;133(3): 716-24 https://doi:
10.1542/peds.2013-2946
107. Donnelly KA, Zocchi MS, Katy TA, Fox ER, Pines JM, van den Anker JN, Mazer-Amirshahi ME. Prescription Drug Shortages:
Pediatric Emergency and Critical Care Medications. Pediatr Emerg Care. 2021 1;37(11): 726-731 https:// doi: 10.1097/
PEC.0000000000001773
108. Li E, Subramanian J, Anderson S, Thomas D, McKinley J, Jacobs IA. Development of biosimilars in an era of oncologic drug
shortages. Drug Des Devel Ther. 2015 24;9:3247-55. https:// doi: 10.2147/DDDT.S75219
109. Pall R, Gauthier Y, Auer S, Mowaswes W. Predicting drug shortages using pharmacy data and machine learning. Health Care
Manag Sci. 2023; 13:1–17. https:// doi: 10.1007/s10729-022-09627-y
110. Cantrell Lee. Stability of active ingredients in long-expired prescription medications. Arch Intern Med. 2012;172(21):1685–
1687 https:// doi: 10.1001/archinternmed.2012.4501
111. Jasinska M, Karwowski B, Orszulak-Michalak D, Kurczewska U. Stability studies of expired tablets of metoprolol tartrate and
propranolol hydrochloride. Part 1. Content determination, Acta Pol Pharm 66 (2009): 697–701 https://pubmed.ncbi.nlm.nih.
gov/20050534/
112. Sharma S, Sharma AK, Moe HW, Khanapure A, Mohan P. A study to investigate the chemical potency, physical stability, and
efficacy of analgesic agents over a period of two years post their expiry date. Med J Armed Forces India. 2022;78(Suppl
1):S194-S200. doi: 10.1016/j.mjafi.2021.03.015
113. Diven D.G., Bartenstein D.W., Carroll D.R. Extending Shelf Life Just Makes Sense. Mayo Clin Proc. 2015;90(11):1471–1474. doi:
10.1016/j.mayocp.2015.08.007 114. Acosta A., Vanegas E.P., Rovira J., Godman B., Bochenek T. Medicine shortages: gaps between countries and global perspectives.
Front Pharmacol. 2019;10 doi: 10.3389/fphar.2019.00763
115. Giammona R, Di-Martino E, Vinci DL, Provenzani, A, and Polidori, P. Hazard vulnerability analysis to evaluate the risk of drug
shortages according to therapeutic class. Br Med J.2020; 116:1–16. https://ejhp.bmj.com/content/ejhpharm/27/Suppl_1/
A194.1.full.pdf
116. Haider A, Qian Y, Lu Z, Naqvi S, Zhuang A, Reddy A. Implications of the parenteral opioid shortage for prescription patterns and
pain control among hospitalized patients with cancer referred to palliative care. JAMA Oncol 2019; 5: 841–846. https:// doi:
10.1001/jamaoncol.2019.0062
117. Rhodes NJ, Gilbert EM, Skoglund E, Esterly JS, Postelnick MJ, Mclaughlin MM. Prediction of inventory sustainability during a
drug shortage. Am J Health-System Pharm. 2016; 73: 1094–1098 https:// doi: 10.2146/ajhp150532
118. Modisakeng C, Matlala M, Godman B, Meyer JC. Medicine shortages and challenges with the procurement process among
public sector hospitals in South Africa; Findings and implications. BMC Health Serv Res. 2020; 20:1–10. https:// doi: 10.1186/
s12913-020-05080-1
119. Lyon J. Drug shortage compounding: the only safe medication source in a time of crisis. Int J Pharm compounding 2012;16:
456–460 https://pubmed.ncbi.nlm.nih.gov/23259360/
120. Meng M, Lv M, Wang L, Yang B, Jiao P, Lei W, Lan H, Shen Q, Luo X, Zhou Q, Yu X, Xun Y, Lei R, Hou T, Chen Y, Li Q. Off-label use
of drugs in pediatrics: a scoping review. Eur J Pediatr. 2022;181(9):3259-3269. doi: 10.1007/s00431-022-04515-7
121. Ekedahl ABE. Reasons why medicines are returned to Swedish pharmacies unused. Pharm. World Sci. 2007;28:352–358.
https://doi: 10.1007/s11096-006-9055-1
122. Lee BK, Ellenbecker MJ, Moure-Ersaso R. Alternatives for treatment and disposal cost reduction of regulated medical wastes.
Waste Manag. 2004; 24(2):143-51. doi: 10.1016/j.wasman.2003.10.008
123. Makki M, Hassali MA, Awaisu A, Hashmi F. The Prevalence of Unused Medications in Homes. Pharmacy (Basel). 2019,
13;7(2):61. doi: 10.3390/pharmacy7020061
124. Smale EM, Egberts TCG, Heerdink ER. Waste-minimising measures to achieve sustainable supply and use of medication.
Sustain Chem Pharm, 2021 ; 21: 1-14 https://doi.org/10.1016/j.scp.2021.100400
Article Sidebar
Published
May 20, 2025
Article Details
How to Cite
1.
Tackling Drug Shortages: An In-Depth Systematic Review Protocol. Pharm Pract (Granada) [Internet]. 2025 May 20 [cited 2025 Jul. 16];23(2):1-8. Available from: https://pharmacypractice.org/index.php/pp/article/view/3176
Section
Original Research
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
How to Cite
1.
Tackling Drug Shortages: An In-Depth Systematic Review Protocol. Pharm Pract (Granada) [Internet]. 2025 May 20 [cited 2025 Jul. 16];23(2):1-8. Available from: https://pharmacypractice.org/index.php/pp/article/view/3176